37.24
Grail Inc Borsa (GRAL) Ultime notizie
How strong is GRAIL LLC company’s balance sheetRetirement Planning Insights With High Returns - jammulinksnews.com
What markets is GRAIL LLC expanding into Is Cadiz Inc. stock a good long term investment optionDiscover high-impact stocks for your portfolio - jammulinksnews.com
What institutional investors are buying GRAIL LLC stockRapid portfolio appreciation - jammulinksnews.com
What makes GRAIL LLC stock price move sharplyAchieve consistent double-digit growth rates - jammulinksnews.com
What analysts say about GRAIL LLC stock outlookCapital Preservation Investment Ideas - metal.it
Is GRAIL LLC a good long term investmentExplosive earning power - PrintWeekIndia
What analysts say about GRAIL LLC stockFree Stock Market Real-Time Monitoring - PrintWeekIndia
"The Grail Collection" Could Be a Game-Changer for MDCE (OTC:MDCE)Jordan, Curry, and NBA Royalty Up for Bid - ACCESS Newswire
Minimal Residual Disease Testing Market Trends Analysis Report 2025-2030 | North America Leads in MRD Testing Market with Advanced Reimbursement Ecosystem - GlobeNewswire Inc.
GRAIL LLC Stock Analysis and ForecastBreakout portfolio performance - Autocar Professional
What drives GRAIL LLC stock priceHigh-yield trading alerts - Autocar Professional
Freenome's new CEO is ready to compete in race for tests that can detect cancer earlySan Francisco Business Times - The Business Journals
(GRAL) Technical Data - news.stocktradersdaily.com
Grail posts latest trial data for Galleri cancer detection test - MSN
Grail’s CFO Freidin sells $311k in common stock By Investing.com - Investing.com India
Grail’s CFO Freidin sells $311k in common stock - Investing.com Australia
Grail (GRAL) PT Hiked to $38 at Morgan Stanley amid ‘Equal Weight’ Stance - MSN
GRAIL’s Galleri Multi-Cancer Test Shows Strong Performance in PATHFINDER 2 Study, Paves Way for FDA Submission - MSN
12 Best Young Stocks To Buy and Hold For 5 Years - Insider Monkey
Illumina: A Compelling Buy Despite GRAIL Divestiture and Macroeconomic Challenges - AInvest
Illumina: Higher Profit Margin Despite GRAIL Divestiture And Macroeconomic Headwinds - Seeking Alpha
Grail (GRAL): A High-Reward, High-Risk Play on Cancer Detection's Future - AInvest
15 Successful Spin-Off Companies and Their 2025 Returns - Insider Monkey
GRAIL Insiders Selling US$10m In Stock Relieved As Market Cap Slides To US$1.7b - simplywall.st
GRAIL's Insider Sales: Red Flag or Strategic Move? Assessing Executive Confidence Amid Strong Financials - AInvest
(GRAL) Trading Report - news.stocktradersdaily.com
GRAIL, Inc.(NasdaqGS: GRAL) dropped from Russell Midcap Index - MarketScreener
Galleri Early Detection Test May Improve Cancer Detection vs SOC Alone - CancerNetwork
Morgan Stanley raises Grail stock price target to $38 on cancer test potential - Investing.com
Grail plans FDA filing for cancer blood test after new trial - pharmaphorum
Grail reports positive outcomes from registrational study of Galleri test - Yahoo Home
PATHFINDER 2 Trial Releases Positive Topline Data for Multicancer Early Detection Test - OncLive
Grail plans to submit updated Galleri blood test for FDA approval next year - Fierce Biotech
Grail stock gains on new data for Galleri cancer test (GRAL) - Seeking Alpha
GRAIL reports positive results from cancer detection test study By Investing.com - Investing.com Nigeria
GRAIL reports positive results from cancer detection test study - Investing.com Australia
GRAIL Announces Positive Top-Line Results From The Galleri PATHFINDER 2 Registrational Study - MarketScreener
Grail reports results from PATHFINDER 2 study - TipRanks
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):